TRAVERE THERAPEUTICS, INC. Marketable Securities, Unrealized Gain (Loss)
TRAVERE THERAPEUTICS, INC. (TVTX) reported Marketable Securities, Unrealized Gain (Loss) of -$4.39 million for the 9-month period ending 2015-09-30, per its 10-Q filed 2015-11-06.
Discontinued › Income Statement › Other Income
us-gaap:MarketableSecuritiesUnrealizedGainLoss · last filed 2015-11-06
- TRAVERE THERAPEUTICS, INC. marketable securities, unrealized gain (loss) for the quarter ending 2015-09-30 was -$876.00K, a 127.53% decline year-over-year.
- TRAVERE THERAPEUTICS, INC. marketable securities, unrealized gain (loss) for the quarter ending 2015-06-30 was -$297.60K.
- TRAVERE THERAPEUTICS, INC. marketable securities, unrealized gain (loss) for the quarter ending 2015-03-31 was -$3.22M, a 699.31% decline year-over-year.
- TRAVERE THERAPEUTICS, INC. marketable securities, unrealized gain (loss) for the quarter ending 2014-12-31 was $694.54K, a 339.23% increase year-over-year.
- TRAVERE THERAPEUTICS, INC. marketable securities, unrealized gain (loss) for fiscal 2014 was $4.40M, a 133421.87% increase from fiscal 2013.
- TRAVERE THERAPEUTICS, INC. marketable securities, unrealized gain (loss) for fiscal 2013 was $3.29K.
| Period end | Marketable Securities, Unrealized Gain (Loss) 3 month | Marketable Securities, Unrealized Gain (Loss) 6 month | Marketable Securities, Unrealized Gain (Loss) 6 month as first filed | Marketable Securities, Unrealized Gain (Loss) 9 month | Marketable Securities, Unrealized Gain (Loss) 9 month as first filed | Marketable Securities, Unrealized Gain (Loss) 12 month | Marketable Securities, Unrealized Gain (Loss) 31 month | Marketable Securities, Unrealized Gain (Loss) 34 month |
|---|---|---|---|---|---|---|---|---|
| 2015-09-30 | -$876.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-06 | -$1.17M derived: sum of 2 quarters · filed 2015-11-06 | -$4.39M 10-Q · filed 2015-11-06 | -$3.70M derived: sum of 4 quarters · filed 2015-11-06 | ||||
| 2015-06-30 | -$297.60K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-10 | -$3.52M 10-Q · filed 2015-08-10 | -$2.82M derived: sum of 3 quarters · filed 2015-08-10 | $357.54K derived: sum of 4 quarters · filed 2015-11-06 | ||||
| 2015-03-31 | -$3.22M 10-Q · filed 2015-05-11 | -$2.53M derived: sum of 2 quarters · filed 2015-05-11 | $655.14K derived: sum of 3 quarters · filed 2015-11-06 | $636.63K derived: sum of 4 quarters · filed 2015-11-06 | ||||
| 2014-12-31 | $694.54K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-11 | $3.88M derived: sum of 2 quarters · filed 2015-11-06 | $3.86M derived: sum of 3 quarters · filed 2015-11-06 | $4.40M 10-K · filed 2015-03-11 | ||||
| 2014-09-30 | $3.18M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-06 | $3.16M derived: sum of 2 quarters · filed 2015-11-06 | $3.70M 10-Q · filed 2015-11-06 | $3.70M 10-Q · filed 2014-11-13 | $3.86M derived: sum of 4 quarters · filed 2015-11-06 | |||
| 2014-06-30 | -$18.52K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-10 | $519.00K 10-Q · filed 2015-08-10 | $1.86M 10-Q · filed 2014-08-14 | $677.13K derived: sum of 3 quarters · filed 2015-08-10 | ||||
| 2014-03-31 | $537.52K 10-Q · filed 2015-05-11 | $695.64K derived: sum of 2 quarters · filed 2015-07-09 | ||||||
| 2013-12-31 | $158.13K derived: 10-K/A 12 month − 10-Q/A 9 month · filed 2015-07-09 | $3.29K 10-K/A · filed 2015-07-09 | $3.29K 10-K/A · filed 2015-07-09 | |||||
| 2013-09-30 | -$154.83K 10-Q/A · filed 2015-07-09 | -$154.83K 10-Q/A · filed 2015-07-09 | ||||||
| 2012-09-30 | $0.00 10-Q · filed 2013-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B |